StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued on Thursday. The firm set a “sell” rating on the stock.

Separately, Benchmark reiterated a “hold” rating on shares of VolitionRx in a research note on Friday, August 16th.

VolitionRx Price Performance

Shares of VNRX stock opened at $0.88 on Thursday. The stock has a market cap of $80.88 million, a P/E ratio of -1.85 and a beta of 1.09. The company has a fifty day moving average price of $0.64 and a two-hundred day moving average price of $0.69. VolitionRx has a one year low of $0.43 and a one year high of $1.23.

VolitionRx (NYSE:VNRX) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.34 million. As a group, equities research analysts anticipate that VolitionRx will post -0.31 EPS for the current fiscal year.

Insider Buying and Selling

In other VolitionRx news, Director Guy Archibald Innes bought 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were acquired at an average cost of $0.67 per share, for a total transaction of $100,500.00. Following the transaction, the director now directly owns 406,683 shares in the company, valued at approximately $272,477.61. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.80% of the stock is owned by corporate insiders.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.